GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
Status:
Completed
Trial end date:
2016-07-29
Target enrollment:
Participant gender:
Summary
This study will evaluate whether low-density lipoprotein (LDL-C) lowering with evolocumab
(AMG 145) results in greater change from baseline in percent atheroma volume (PAV) at week 78
than placebo in adults with coronary artery disease taking lipid lowering therapy.